Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: Which drugs for which patients?

Fundamental and Clinical Pharmacology

Volumn 23, Issue 6, 2009, Pages 687-692

  Drexel, Heinz ^a,b,c,d  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b Academic Teaching Hospital Feldkirch   (Austria)

^c PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anion exchange resins; Ezetimibe; Fibrates; Lipid lowering drugs; Niacin; Statins

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANION EXCHANGE RESIN; ATORVASTATIN; CHOLESTEROL ESTER; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; ROSUVASTATIN; SIMVASTATIN; STEROID RECEPTOR COACTIVATOR 1; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID ABSORPTION; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TACHYPHYLAXIS;

ANION EXCHANGE RESINS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RISK REDUCTION BEHAVIOR;

EID: 70449484628     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00745.x     Document Type: Review

References (34)

1. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia (2003) 46 733 749.
2. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet (2005) 365 1415 1428.
3. Watts G.F., Barrett P.H., Chan D.C. HDL metabolism in context: looking on the bright side. Curr. Opin. Lipidol. (2008) 19 395 404.
4. Stancu C., Sima A. Statins: mechanism of action and effects. J. Cell Mol. Med. (2001) 5 378 387.
5. Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366 1267 1278.
6. Kearney P.M., Blackwell L., Collins R. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 371 117 125.
7. Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350 1495 1504.
8. LaRosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352 1425 1435.
9. Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110 227 239.
10. AAS Cholesterinkonsensus. Accessed on 19-04-09 on http://www.aas.at/docs/ chol-konsensus06.pdf
11. Black D.M. Gut-acting drugs for lowering cholesterol. Curr. Atheroscler. Rep. (2002) 4 71 75.
12. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (2002) 251 351 364.
13. Bays H.E., Neff D., Tomassini J.E., Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert. Rev. Cardiovasc. Ther. (2008) 6 447 470.
14. Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. (2008) 359 1343 1356.
15. Barter P.J., Caulfield M., Eriksson M. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. (2007) 357 2109 2122.
16. Brown B.G., Zhao X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am. J. Cardiol. (2008) 101 58B 62B.
17. Canner P.L., Berge K.G., Wenger N.K. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. (1986) 8 1245 1255.
18. Brown B.G., Zhao X.Q., Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345 1583 1592.
19. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 110 3512 3517.
20. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. Accessed on 19-04-09 on http://www.clinicaltrials.gov.
21. Niacin Plus Statin to Prevent Vascular Events. http://www.clinicaltrials. gov. Accessed on 19-04-09 on http://www.clinicaltrials.gov.
22. Barter P.J., Rye K.A. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation (2006) 113 1553 1555.
23. Frick M.H., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. (1987) 317 1237 1245.
24. Rubins H.B., Robins S.J., Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341 410 418.
25. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102 21 27.
26. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes. Metab (2009) 11 89 94.
27. McKenney J.M., Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy (2007) 27 715 728. (Pubitemid 46700964)
28. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet (1999) 354 447 455.
29. Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 372 1223 1230.
30. Marchioli R., Levantesi G., Macchia A. et al. Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J. Membr. Biol. (2005) 206 117 128.
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360 7 22.
32. Knopp R.H., Gitter H., Truitt T. et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. (2003) 24 729 741.
33. Clark R.W., Sutfin T.A., Ruggeri R.B. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. (2004) 24 490 497.
34. Robinson J.G., Wang S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. (2009) 53 316 322.